BioTuesdays
Ortho Regenerative Technologies

Ortho RTi to begin trading on CSE today

Ortho Regenerative Technologies will begin trading today on the Canadian Securities Exchange under the stock symbol, ORTH. Ortho RTi is an emerging orthopedic and sports medicine technology company with a focus on novel...

Alcobra_Arcturus

Alcobra and Arcturus agree to merge

Alcobra (NASDAQ:ADHD) announced plans to merge with closely held Arcturus Therapeutics in an all-stock transaction, creating an RNA-focused company with a 40-60 split in ownership, respectively. Arcturus’ technology...

American CryoStem

American CyroStem expands China relationship

American CryoStem (OTC:CRYO) has expanded its relationship with Health Innovative Technology (HIT) of Hong Kong. After more than two years as CryoStem’s licensee in Hong Kong, HIT has licensed the patent rights to...

Evotec

MaRS Innovation in collaboration with Evotec AG

MaRS Innovation and Evotec AG (FSE:EVT) have launched LAB150, a Toronto-based partnership to tap infrastructure and drug discovery expertise of Evotec and drug discovery projects from the 15-member institutions of MaRS...

Titan Pharmaceuticals Logo

Titan’s Probuphine featured on CBS affiliate

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine...

Opiant Pharmaceuticals

Opiant approved for NASDAQ listing

Shares of Opiant Pharmaceuticals were approved for listing on the Nasdaq Capital Market at the opening tomorrow (August 29) under the symbol, OPNT.  The company’s common stock had traded on the OTCQB Marketplace since...

Aphria Scientus Pharma

Scientus Pharma gets investment from Aphria

Aphria (TSX:APH; OTCQB:APHQF) has invested $11.5-million in Scientus Pharma’s HydRx Farms unit by way of a 2-year secured debenture convertible into common shares of Scientus Pharma at a rate of $2.75 a share...

microbix

Microbix posts 23% jump in Q3 revenue

Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year...